Shaily Engineering Plastics Limited (SHAILY) — Multibagger Analysis

AI research on 1 Expansion / Order-win announcement by Shaily Engineering Plastics Limited since August 2026 — deal magnitude, revenue and EPS impact, execution risk, and the actual return since each announcement measured from the next trading day's open and benchmarked against the Nifty Smallcap 250.

Investor Presentation

08 August 2026 · Expansion · Strong Candidate · Plastics Products · score 78/100

Deal

Deal value—

Deal vs businessHealthcare Q1 FY27 revenue reached ₹142.4 Cr (+85% YoY), now >50% of total revenue; 2 new IP platform projects signed.

Execution period1.0 yr

Fundamental gradeA

AI projections

Revenue uplift (yr1 / steady)15.0% / 28.0%

EPS uplift32.0%

Upside base / bull / bear35.0% / 70.0% / -25.0%

Horizon12-36 months

Realized market record

Entry — next-day open (10 Aug 2026)₹3131.8

Latest close (16 Oct 2026)₹3109.7

Return since-0.7%

α vs Smallcap 250+3.3%

α vs own sectorshown once held 90+ days — Plastics Products median is -36.6% over 8 matured picks

Positives

Healthcare segment revenue grew 85% YoY to ₹142.4 Cr, crossing 50% of overall company revenue.
EBITDA margins expanded 120 bps YoY to 29.7% due to favorable product mix toward proprietary IP pen injectors.
Regulatory approvals secured in key markets (USFDA tentative, Health Canada, Brazil, India) for proprietary Semaglutide pen injectors.
Exceptional return metrics with TTM ROCE at 30.0% and Q1 FY27 annualized ROCE reaching 39.0%.

Risks

Consumer segment weakness (-24% YoY to ₹115.5 Cr) due to macroeconomic slowdown in European and US home furnishing markets.
Customer concentration risk remains elevated with major MNC pharma and consumer clients dictating revenue trajectory.
Regulatory delays in pharma dispatches could defer delivery schedules by 12-14 months.

Full AI brief

Shaily Engineering Plastics (SHAILY) - Q1 FY27 Investor Presentation Analysis

Executive Summary

Shaily Engineering Plastics reported its Q1 FY27 financial performance and updated investor presentation. Revenue grew 14% YoY to ₹280.7 Cr, driven by an outstanding 85% YoY expansion in the Healthcare segment (₹142.4 Cr). Healthcare now accounts for >50% of total revenues, successfully pivoting the business from lower-margin consumer plastics into high-margin, regulatory-moated drug delivery devices (e.g., proprietary Semaglutide GLP-1 pen injectors).

1. Quality Gate & Fundamental Grade

Fundamental Grade: A (SEPA Framework)
ROCE / ROE: ROCE stands at 30.0% TTM and reached 39.0% annualized in Q1 FY27. Debt/Equity remains conservative at 0.27x (Debt: ₹175 Cr, Net Worth: ₹649 Cr).
Margin Expansion: Consolidated EBITDA margins expanded to 29.7% (+120 bps YoY), reflecting the gross-margin accretive nature of IP-led healthcare devices vs. consumer plastic components.

2. Ramp-Aware Catalyst & Financial Impact

Healthcare Segment Surge: Healthcare quarterly run-rate crossed ₹142 Cr (annualized ~₹570 Cr). Commercial supplies of Semaglutide pen injectors in Canada, Brazil, and India, coupled with USFDA tentative approval, set up strong volume scalability.
Consumer Drag Offset: A 24% YoY drop in consumer business (to ₹115.5 Cr) due to soft European/US home furnishing demand was easily absorbed by healthcare growth.
Financial Valuation Math:
Q1 FY27 PAT: ₹48.0 Cr (+17% YoY).
Annualized EPS: ~₹41.9 / share vs FY26 EPS of ₹36.59.
Steady-state FY28 Forecast: As GLP-1 generic rollouts accelerate, healthcare segment annual revenue is projected to cross ₹750 Cr. At 30% EBITDA and ~18% PAT margins, total consolidated revenue could reach ₹1,350 Cr with PAT at ₹240 Cr (EPS ~₹52.3).

3. Valuation & Scenario Analysis

Current Trailing P/E: 86.4x on TTM EPS of ₹36.59.
Base Case (+35% upside): Earnings CAGR of ~30-35% driven by GLP-1 volume ramp-up. P/E moderates to ~65x on FY28 EPS of ₹65, driving price target to ~₹4,225.
Bull Case (+70% upside): Rapid US generic Semaglutide adoption + commercialization of two newly signed IP platform projects. FY28 EPS reaches ₹75 with multi-year premium valuation maintained at ~70x P/E, targeting ~₹5,350.
Bear Case (-25% downside): USFDA inspection/regulatory delays (12-14 month dispatch block) combined with continued decay in consumer segment. EPS stalls around ₹40, trailing P/E derates to 60x, lowering price to ~₹2,400.

4. Verdict & Rationale

Verdict: STRONG_CANDIDATE Shaily is demonstrating a textbook fundamental transformation: shifting product mix from cyclical consumer plastics to high-barrier healthcare IP devices. Strong balance sheet (D/E 0.27), high ROCE (39% Q1 annualized), and dominant exposure to global generic GLP-1 pen delivery platforms make it a high-conviction growth compounder.

Analysis as of 2026-08-08 (price ₹3162.30) · AI research, not investment advice.

FollowTelegram

Verdicts and projections on this page are produced by an AI model from Shaily Engineering Plastics Limited's public exchange filings and are not investment advice. "Return since" is measured from the opening price of the next trading day after each announcement to the latest available close, so it reflects a price an investor could actually have paid. See all analysed companies on Multibagger AI.